Retour au classement

Envista Holdings Corporation (NVST)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

Fondamental

55

Prix

$27.25

Capitalisation boursière

$4.40B

Partie 1 · Ce que vaut l'entreprise

Vue d'ensemble

Envista makes the products dentists and orthodontists use every day: dental implants, clear aligners and orthodontic brackets, plus the equipment and consumables — imaging systems, drills, cements, infection-control supplies — that keep a dental office running. It sells through its own sales force and a network of dealers to over 130 countries, serving both specialists who place implants and general practitioners who handle routine care. More than half its sales come from outside the United States.

Comment l'entreprise gagne de l'argent

Envista books revenue when it ships implants, aligners, equipment or consumables to dealers and dental practices; consumables and implants are recurring, replenished purchases, while imaging systems and other capital equipment are one-off, lumpier sales tied to a practice's investment cycle. Its two segments split roughly two-thirds specialty products (implants, orthodontics) to one-third equipment and consumables, and its largest single distributor, Henry Schein, alone channels about 12% of total sales to end customers.

Chiffre d'affaires par segment

Specialty Products & Technologies64.4%

Dental implant systems, regenerative products and orthodontic brackets, aligners and lab products for specialists and general dentists.

Equipment & Consumables35.6%

Dental imaging systems, endodontic equipment, restorative materials, cements and infection-prevention supplies used in daily practice.

Avantage concurrentiel

Économies d'échelle · Étroit

Envista describes itself as running one of the largest customer-facing sales teams in the dental industry, backed by a global dealer network reaching over 130 countries. That distribution scale is hard for smaller rivals to match, but the underlying implant and equipment categories are competitive and price-sensitive, so the advantage is narrow rather than a lock on the market.

Ce qui stimule la demande

Modérément cyclique

Routine dental consumables track fairly steady patient visit volumes, but elective procedures like implants and big-ticket equipment purchases are more discretionary and get postponed when practices or patients tighten spending. The mix of the two makes overall demand more resilient than typical consumer discretionary goods, but not fully immune to economic cycles.

Principaux risques

  • Distributor dependence — A substantial portion of sales flows through a limited number of distributors, chiefly Henry Schein, with no assurance any of them will keep purchasing at current levels or that lost volume could be quickly replaced.
  • Distributor inventory swings — The company relies on predictions of distributor and customer inventory levels to plan production; when those inventories build or run down differently than expected, reported results can diverge sharply from underlying demand.
  • Acquisition and divestiture risk — Envista routinely acquires and divests businesses to fit its portfolio strategy, and warns that earn-outs, indemnification obligations, goodwill impairments and unsatisfied deal conditions could all produce unpredictable financial results.

Concentration des clients

Les principaux clients représentent 12% du chiffre d'affaires

Henry Schein, the company's largest distributor, accounted for approximately 12% of sales in 2025 and is expected to remain the top contributor for the foreseeable future, without a master distribution agreement guaranteeing that relationship.

Les arguments en faveur

Buyers argue that Envista's scale in global dental distribution and its position across both the specialist implant market and everyday consumables give it a resilient, recurring revenue base that should benefit as dental procedure volumes recover outside the U.S.

Les arguments contre

Sellers fear that heavy reliance on a handful of distributors, led by Henry Schein, leaves Envista exposed to a single relationship it does not fully control, and that elective procedure volumes remain vulnerable if patients keep deferring discretionary dental work.

Données par segment de l'exercice 2025Sources: Envista Holdings Corp — Form 10-K, fiscal year 2025

Written by the editors, published on 18 août 2026

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Bilan & Liquidités

Chiffre d'affaires

$2.86B

12 derniers mois (au 03/07/2026)

Résultat net

$95M

12 derniers mois (au 03/07/2026)

Flux de trésorerie libre

$230M

Capitaux propres totaux

$3.11B

Passif total

$2.57B

Ratio de liquidité général

2.43

Couverture des intérêts

-

Dette/EBITDA

4.78

Bénéfice par action

Chiffre d'affaires & Résultat net

Flux de trésorerie libre

Décomposition du résultat

État historique

Marges dans le temps

La dette dans le temps

Le poids de la dette

Grille de la croissance

Croissance — Chiffre d'affaires

Estimation de la juste valeur

Justement valorisé

Juste valeur

$24.42

Prix actuel

$27.25

Marge de sécurité

-11.6%

Fourchette de juste valeur

$15.88 - $32.97

Méthodes d'estimation

Analyst Target:$30.57
DCF:$38.28
PE-based:$10.29
Graham Growth:$10.96
EPV:$14.11
Consensus des analystes:Acheter (12B / 10H / 0S)
Dernière surprise sur les résultats:+19.92%

Indicateurs de valorisation

Ratio P/E

47.14

ROE

1.5%

Ratio P/B

1.43

P/FCF

17.70

Marge brute

55.2%

ROIC

4.5%

Radar de rentabilité

Value Creation (Economic Moat)

ROIC

4.5%

WACC

6.9%

ROIC − WACC

-2.4 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

Critères d'analyse fondamentale

Réussi (17)

  • Gross Margin 55.2%
  • P/FCF 17.70
  • P/B Ratio 1.43
  • Debt/Equity ratio
  • Operating Margin 9.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Revenue Growth 5Y 7.1%
  • Analyst Consensus 55% Buy
  • Earnings Surprise avg 15.7%
  • Earnings Quality (OCF/NI) 3.19
  • Share Dilution -2.5%
  • Net Margin Trend 3.3% vs 2.1%
  • Piotroski F-Score 7/9

Échoué (9)

  • EPS shows upward trend
  • EPS CAGR -23.35%
  • Price CAGR -1.22%
  • ROIC 4.5%
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Fairly valued)
  • ROE 3.1%
  • PEG Ratio 7.29

Indisponible (2)

  • Dividend Payout NaN%
  • Interest Coverage

Score F de Piotroski

7/9

Santé financière solide

score
criteria

Qualité des bénéfices

3.19

Qualité élevée : bénéfices soutenus par la trésorerie

Dilution du capital

-2.5%

Rachat d'actions. Favorable aux actionnaires

Gouvernance

Équipe dirigeante

NomTitreÂge
Mr. Eric D. HammesSenior VP & CFO50
Mr. Mark E. Nance J.D.Senior VP, General Counsel & Secretary56
Mr. Robert Befidi Jr.Senior VP & President of Diagnostics50
Ms. Veronica AcurioSenior VP & President of Orthodontics54
Mr. Coree ThomasVP & Chief Accounting Officer47
Mr. Andrew ChenChief Information Officer-
Mr. Jim GustafsonVice President of Investor Relations-
Paul SumilasChief Compliance Officer-
Mr. Mischa M. ReisSenior Vice President of Strategy & Corporate Development52
Mr. Suraj SatpathyChief Human Resources officer-

Risque d'audit

2

Risque du conseil

2

Risque de rémunération

4

Risque droits des actionnaires

5

Partie 2 · Le prix et le moment d'entrer

Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.

Latest News

Recent headlines for NVST, sourced from Markets Gazette.

No recent news for NVST.